Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Abbott Laboratories (NYSE: ABT), an Illinois-incorporated healthcare company whose common shares are listed on the New York Stock Exchange. Through these filings, investors can review official disclosures on Abbott’s operations, governance, financial reporting practices and material corporate events.
Abbott’s SEC filings include periodic reports and current reports on Form 8-K. Recent 8-K filings describe matters such as the entry into an Agreement and Plan of Merger with Exact Sciences Corporation, under which a wholly owned Abbott subsidiary will merge with Exact Sciences, with Exact Sciences surviving as a direct, wholly owned subsidiary of Abbott subject to customary closing conditions. Another 8-K details a notice of a blackout period for certain employee benefit plans due to administrative changes, including recordkeeper, trustee and custodian transitions, and outlines related trading restrictions for directors and executive officers. Additional 8-K disclosures cover corporate governance updates, such as amendments to Abbott’s by-laws to change the size of the board of directors and the appointment of a new director, as well as announcements of quarterly financial results and the company’s use of non-GAAP financial measures.
On Stock Titan, each new Abbott filing from the SEC’s EDGAR system can be viewed alongside AI-powered summaries that explain key points in clear language. These summaries help readers quickly understand topics like merger terms, benefit plan blackout periods, board changes, or how management presents adjusted financial metrics, without having to parse every technical detail. Users can also review exhibits referenced in the filings, such as merger agreements, notices to directors and officers, and amended by-laws, to see the underlying legal documents.
For those tracking insider-related information, governance changes or major transactions, Abbott’s SEC filings offer an authoritative record of the company’s regulatory disclosures, while AI-generated insights on this page aim to make those documents more accessible and easier to interpret.
ABBOTT LABORATORIES executive Christopher J. Scoggins reported equity awards consisting of stock options and performance-based shares. He received an employee stock option for 76,273 common shares at an exercise price of $0.0000 per share, granted under the Abbott Laboratories 2017 Incentive Stock Program.
The option becomes exercisable in three annual increments of 25,424 shares on February 24, 2027, 25,424 shares on February 24, 2028, and 25,425 shares on February 24, 2029. He was also granted 18,502 common shares as a performance-based restricted stock award with a three-year term, with no more than one‑third vesting in any year upon Abbott reaching a minimum return on equity target, and the award allows shares to be withheld for taxes.
ABBOTT LABORATORIES executive Daniel Gesua Sive Salvadori reported awards of equity-based compensation. He received an option to buy 89,226 Abbott shares at an exercise price of $0.00 per share under the 2017 Incentive Stock Program, with the option becoming exercisable in three equal annual installments of 29,742 shares on February 24, 2027, February 24, 2028, and February 24, 2029. He also acquired 21,644 common shares as a performance-based restricted stock award with a three-year term, where no more than one-third of the award can vest in any one year, subject to Abbott reaching a minimum return on equity target, and the award allows shares to be withheld to cover taxes.
ABBOTT LABORATORIES executive Louis H. Morrone reported equity awards granted on February 24, 2026. He acquired an option to buy 63,561 Abbott shares at an exercise price of $0.00 per share and a grant of 15,418 common shares, both reported as direct ownership.
The 15,418-share award is performance-based restricted stock under the Abbott Laboratories 2017 Incentive Stock Program with a 3‑year term, where no more than one‑third can vest in any year and vesting depends on Abbott reaching a minimum return on equity target, and it allows shares to be withheld for taxes. The stock option, also under the 2017 Incentive Stock Program, was granted in a transaction exempt from Section 16 under Rule 16b‑3 and becomes exercisable in three equal annual installments of 21,187 shares on February 24, 2027, February 24, 2028, and February 24, 2029. The filing also notes an indirect holding of 12 Abbott shares in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.
Moreland Mary K reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive vice president Mary K. Moreland reported equity awards on common stock. She received an employee stock option covering 57,512 shares that vests in three annual installments starting February 24, 2027, and a performance-based restricted stock award of 13,951 shares with a three-year term tied to return-on-equity targets.
Abbott Laboratories executive John A. McCoy Jr., Vice President and Controller, reported equity awards on February 24, 2026. He acquired an employee stock option for 22,151 options with no purchase price, which vests in three annual installments beginning in 2027. He also received a performance-based restricted stock award of 5,373 common shares that can vest over three years if Abbott meets a minimum return-on-equity target, with shares eligible to be withheld for taxes. Separately, he reported 58 common shares held indirectly in the Abbott Laboratories Stock Retirement Trust as of that date.
Abbott Laboratories Chairman and CEO Robert B. Ford reported equity awards rather than open-market trades. He acquired 344,066 options with a zero-dollar grant price under the Abbott Laboratories 2017 Incentive Stock Program, scheduled to become exercisable in three equal annual installments starting on February 24, 2027.
Ford also received a performance-based restricted stock award of 83,464 common shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target. An additional 216,203 common shares are reported as held indirectly through the Ford Family Trust, where he serves as co-trustee.
Earnhardt Lisa D reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive Lisa D. Earnhardt, EVP and Group President, reported equity awards on February 24, 2026. She was granted stock options covering 111,533 options and a performance-based restricted stock award of 27,056 common shares under the Abbott Laboratories 2017 Incentive Stock Program.
The restricted stock award has a three-year term, with no more than one-third vesting in any year and vesting tied to Abbott reaching a minimum return-on-equity target. The award allows shares to be withheld for taxes. The stock option becomes exercisable in increments of 37,177 and 37,178 shares on February 24, 2027, February 24, 2028, and February 24, 2029.
Cushman Elizabeth C. reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive Elizabeth C. Cushman, EVP, GC and Secretary, reported equity awards on February 24, 2026. She received an employee stock option for 61,964 options under the Abbott 2017 Incentive Stock Program, exercisable in three annual installments starting in 2027. She was also granted 15,031 performance-based restricted shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target and allowing shares to be withheld for taxes.
ABBOTT LABORATORIES executive Philip P. Boudreau, EVP and CFO, reported equity awards. On February 24, 2026, he acquired an employee stock option for 115,413 shares with no exercise price shown here, granted under the Abbott Laboratories 2017 Incentive Stock Program and scheduled to become exercisable in three equal annual installments beginning February 24, 2027.
On the same date, he also received a performance-based restricted stock award of 27,997 common shares without par value, with a three‑year term and no more than one‑third vesting in any year, contingent on Abbott reaching a minimum return on equity target and allowing share withholding for taxes. Following these awards, he directly owned 78,613 common shares and indirectly held 366 shares through an Abbott Laboratories Stock Retirement Trust as of February 24, 2026.
Abbott Laboratories entered into a pricing agreement to issue and sell $20,000,000,000 aggregate principal amount of senior notes across eight tranches, including Floating Rate Notes due 2029 and Fixed Rate Notes with coupons from 3.700% to 5.600% maturing between 2029 and 2066.
The notes were priced through a syndicate led by major underwriters and offered under Abbott’s effective shelf registration statement via a prospectus and prospectus supplement. Closing of the notes offering is expected on March 9, 2026, subject to customary conditions.
Abbott plans to use the net proceeds, together with cash on hand and/or additional borrowings, to fund consideration for its proposed acquisition of Exact Sciences Corporation, repay certain Exact Sciences indebtedness, cover related fees and expenses, and for general corporate purposes, which may include repayment of other debt.